NCT06843408

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Systemic Therapy

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.

Conditions

• Chronic Graft-versus-host-disease

Interventions

Type	Name	Description
DRUG	INCA034176	IV infusion

Timeline

• Start date: 2025-06-25
• Primary completion: 2026-07-03
• Completion: 2027-12-31
• First posted: 2025-02-25
• Last updated: 2026-02-03

Locations

9 sites across 1 country: China

Regulatory

• FDA-regulated drug study